Cargando…
Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report
Statins are the most widely used cholesterol-lowering drugs for cardiovascular diseases prevention. However, some patients are refractory to treatment, whereas others experience statin-related adverse events (SRAE). It has been increasingly important to identify pharmacogenetic biomarkers for predic...
Autores principales: | Dagli-Hernandez, Carolina, de Freitas, Renata Caroline Costa, Marçal, Elisangela da Silva Rodrigues, Gonçalves, Rodrigo Marques, Faludi, Andre Arpad, Borges, Jéssica Bassani, Bastos, Gisele Medeiros, Los, Bruna, Mori, Augusto Akira, Bortolin, Raul Hernandes, Ferreira, Glaucio Monteiro, de Oliveira, Victor Fernandes, Hirata, Thiago Dominguez Crespo, Hirata, Mario Hiroyuki, Hirata, Rosario Dominguez Crespo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859822/ https://www.ncbi.nlm.nih.gov/pubmed/33553369 http://dx.doi.org/10.21037/atm-20-5540 |
Ejemplares similares
-
A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics
por: Lehtisalo, Minna, et al.
Publicado: (2022) -
Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia
por: Wagner, Jonathan B., et al.
Publicado: (2020) -
Ethylmethylhydroxypyridine Succinate Is an Inhibitor but Not a Substrate of ABCB1 and SLCO1B1
por: Shchulkin, Aleksey V., et al.
Publicado: (2023) -
SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria
por: Sortica, Vinicius A, et al.
Publicado: (2017) -
SLCO1B1 Polymorphism is not associated with Risk of Statin-Induced Myalgia/Myopathy in a Czech Population
por: Hubáček, Jaroslav A., et al.
Publicado: (2015)